With these precedents we decided to investigate the role of HMGB1, HMGB2, MIEN1 and NOP53 in cell viability as well as in response and sensitivity to drugs currently used in ovarian cancer therapy. The gene discussed is HMGB2; the disease is ovarian cancer.